Muenchen Klinik gGmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Muenchen Klinik gGmbH, the cardiology team is investigating innovative approaches to manage heart attacks, focusing on patients at risk of a recurrent event. The study evaluates the effectiveness of a self‑administered medication to quickly address symptoms of acute myocardial infarction, aiming to improve early treatment outcomes and reduce hospital admissions.
- Early patient‑initiated therapy for heart attacks
- Assessment of real‑world effectiveness
- Safety monitoring of self‑administration
- Impact on recurrent cardiovascular events
- Integration of emergency response protocols
The research involves a multidisciplinary team of 13 investigators and leverages the hospital’s intensive care expertise in Munich to advance cardiovascular care.
Neoplasms
The oncology department is conducting cutting‑edge trials in metastatic colorectal cancer, particularly in patients whose tumors exhibit MSI‑High or mismatch repair deficiency. By testing novel immunotherapy combinations, including agents such as MK‑1308A alongside established checkpoint inhibitors, the goal is to enhance tumor response rates and provide new treatment options for advanced disease.
- Biomarker‑driven immunotherapy strategies
- Combination regimens to boost response
- Evaluation of objective response per RECIST
- Safety and tolerability of new agents
- Optimizing dosing for targeted therapies
With 13 dedicated investigators, the Munich site is positioned to contribute valuable data to the global effort against colorectal cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 108 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 108 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1AstraZeneca AB5active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Muenchen Klinik gGmbH
lock Showing 1 of 63 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial | Fondazione GONO G.I. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 108 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 16 | Unknown | 2016-11-07 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.